$2.11
-4.5%Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ACTU • NASDAQ
| Actuate Therapeutics Inc Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
13.2M | 8.6M | 3M | 20.4M | |
13.2M | 8.6M | 3M | 20.4M | |
0.0 | 566.3K | 0.0 | 0.0 | |
484K | 0.0 | 36.9K | 33.7K | |
13.6M | 9.2M | 3M | 20.5M | |
NON-CURRENT ASSETS | ||||
392.5K | 110.5K | 0.0 | 0.0 | |
392.5K | 110.5K | 0.0 | 0.0 | |
14M | 9.3M | 3M | 20.5M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
1.5M | 1.9M | 3.4M | 2.1M | |
1.5M | 1.9M | 3.4M | 2.1M | |
0.0 | 6.9M | 3.2M | 132K | |
4.2M | 0.0 | 277.5K | 2.1M | |
5.7M | 8.8M | 6.9M | 4.3M | |
NON-CURRENT LIABILITIES | ||||
405K | 0.0 | 0.0 | 405K | |
0.0 | 411.8K | 95.7M | 900.8K | |
405K | 411.8K | 95.7M | 1.3M | |
6.1M | 9.2M | 102.6M | 5.7M | |
SHAREHOLDERS' EQUITY | ||||
0.0 | 0.0 | 0.0 | 90.1M | |
23.0 | 20.0 | 2.0 | 3.0 | |
162.5M | 132.5M | 5.5M | 5M | |
-154.6M | -132.4M | -105.1M | -80.3M | |
0.0 | -834.0 | 1.0 | 0.0 | |
7.9M | 104.2K | -99.6M | 14.8M | |
7.9M | 104.2K | -99.6M | 14.8M | |
SUMMARY | ||||
14M | 9.3M | 3M | 20.5M | |
405K | 0.0 | 0.0 | 405K | |
-12.8M | -8.6M | -3M | -20M | |
20,743,309 | 20,743,309 | 20,743,309 | 20,743,309 |
ACTU - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 21, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your ACTU research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.